Evidence map›Paper›PMID 33498502›Full record

ReviewCancers2021

Cancer Stem Cells-Key Players in Tumor Relapse.

Monica Marzagalli, Fabrizio Fontana, Michela Raimondi, Patrizia Limonta

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Monica MarzagalliDepartment of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milano, Italy.
Fabrizio FontanaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milano, Italy.
Michela RaimondiDepartment of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milano, Italy.ORCID 0000-0002-2965-509X
Patrizia LimontaDepartment of Pharmacological and Biomolecular Sciences, University of Milan, via Balzaretti 9, 20133 Milano, Italy.ORCID 0000-0001-7028-3008

Funding

AIRC Fellowship for ItalyDepartmen of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano MIUR Progetto di Eccellenza
6 · The paper itself

Abstract

Tumor relapse and treatment failure are unfortunately common events for cancer patients, thus often rendering cancer an uncurable disease. Cancer stem cells (CSCs) are a subset of cancer cells endowed with tumor-initiating and self-renewal capacity, as well as with high adaptive abilities. Altogether, these features contribute to CSC survival after one or multiple therapeutic approaches, thus leading to treatment failure and tumor progression/relapse. Thus, elucidating the molecular mechanisms associated with stemness-driven resistance is crucial for the development of more effective drugs and durable responses. This review will highlight the mechanisms exploited by CSCs to overcome different therapeutic strategies, from chemo- and radiotherapies to targeted therapies and immunotherapies, shedding light on their plasticity as an insidious trait responsible for their adaptation/escape. Finally, novel CSC-specific approaches will be described, providing evidence of their preclinical and clinical applications.

Indexed as

cancer stem cellschemotherapydrug resistanceimmunotherapiesmolecular mechanismsradiation therapytargeted therapies

Identifiers

PMID33498502
PMCPMC7864187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.